<DOC>
	<DOCNO>NCT00304655</DOCNO>
	<brief_summary>The purpose study prove safety efficacy aripiprazole .</brief_summary>
	<brief_title>Acute Psychosis Treatment Long Term , Unitary Group Study ( APLUS )</brief_title>
	<detailed_description>This study design prove safety efficacy aripiprazole treatment acutely relapse patient diagnose schizophrenia schizoaffective disorder Korea confirm maintenance efficacy safety maintenance period change emotional factor social function . After administer 15 mg/day aripiprazole two week , test may change dose within range 10 mg 30 mg per day clinical judgment . ( Medication duration : 8 week ( acute phase ) + 18 week ( maintenance phase ) ] + 26 week ( extension phase ) , *total 52 week )</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>1 . Schizophrenia schizoaffective disorder patient define DSMIV criterion acute relapse 2 . 18 65 year 3 . Males female ( female child bear potential must use acceptable contraception must pregnant lactating ; female childbearing potential must negative serum pregnancy test ) 4 . Randomization study must occur four week follow day initiation treatment present episode/relapse . 5 . Should total PANSS score least 60 . In addition , patient score least 4 ( `` moderate '' ) two four PANSS item constitute psychotic item subscale ( hallucinatory behavior , delusion , conceptual disorganization , suspiciousness ) . 6 . Patients must able rat reliably battery psychiatric movement rating scale require protocol . 7 . Patients eligible enter study must sign informed consent form . 1 . Patients violent 2 . Patients , opinion investigator , serious suicidal ideation 3 . Patients liable serious suicide attempt , clinical judgment 4 . Patients currently psychiatric diagnosis schizophrenia , schizophrenic form disorder schizoaffective disorder require pharmacotherapy 5 . Patients follow neurologic diagnosis : migraine , epilepsy , Parkinson 's disease , Alzheimer 's disease , multiple sclerosis , residual stroke , transient cerebral ischemic attack , `` cerebral palsy '' condition require intermittent maintenance treatment , manifest abnormality neurologic examination 6 . Patients must continue take , may potentially need take , study , follow concomitant medication , could cause unwanted drugtodrug interaction could confound analysis antipsychotic effectiveness : Tegretol ( carbamazepine ) , Depakene Depakote ( valproic acid sodium valproate divalproate sodium ) , Lithium carbonate lithium citrate 7 . Patients treatment schizophrenia : take antipsychotic drug ( consta ) randomization 8 . Patients must continue take , study , drug substance know strong suppressive agent microsomal enzyme CYP2D6 9 . Patients gastrointestinal resection , stomach stapling , condition may impair absorption study medication 10 . Patients currently meet DSMIV criterion psychoactive substance dependence patient history substance alcohol dependence ( accord DSMIV criterion ) within one month prior begin study 11 . Patients somatic condition whose symptom physical sign could misinterpret sign symptoms psychosis adverse effect antipsychotic medication . 12 . Patients acute unstable medical condition require pharmacotherapy 13 . Patients abnormal laboratory test result judge investigator 14 . Patients participate previous aripiprazole clinical study 15 . Patients take investigational drug within four week precede start placebo washout</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective disorder</keyword>
	<keyword>Aripiprazole</keyword>
</DOC>